Evidence Hub

Efficacy and safety of dupilumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis

L. Sim, Norasnieda Binti Md Shukri, N. Yaacob, Chenthilnathan Periasamy, Musat Gabriela Cornelia, Baharudin Abdullah

Expert Review of Clinical Pharmacology, 2025

784 participants · 3 citations

Abstract

ABSTRACT Introduction Chronic rhinosinusitis with nasal polyps (CRSwNP) primarily displays type 2 inflammation, characterized by the activation of interleukin (IL)-4, IL-5, and IL-13 in the pathway. The purpose of this study is to determine the efficacy and safety of dupilumab (an IL-4 antagonist) in treating CRSwNP. Methods A detailed search was performed in PubMed, Embase and the Cochrane Library databases. All published English-language randomized controlled trials (RCTs) that employed dupilumab to treat CRSwNP in adult patients (≥18 years old) were considered. Results Three RCTs and 25 studies with 784 individuals were included. The use of dupilumab revealed improvement in polyp size (MD −1.80; 95% CI −2.25 to −1.36), Lund-Mackay score (MD −7.01, 95% CI −9.64 to −4.38), congestion (MD −0.86, 95% CI −0.99 to −0.73), smell (MD 10.83, 95% CI 9.59 to 12.08) and health-related quality of life (MD −19.61, 95% CI −22.53 to −16.69). Systemic corticosteroid use (RR 0.28, 95% CI 0.20–0.39) and revision surgery (RR 0.17, 95% CI 0.05–0.52) were reduced. Serious adverse events were reduced in dupilumab group (RR 0.47; 95% CI 0.29 to 0.76) with no change in risk of adverse events (RR 0.98, 95% CI 0.87 to 1.11). Conclusions Dupilumab is effective with minimal adverse events. Protocol registration www.crd.york.ac.uk/prospero identifier is CRD42023413004.

How strong is the evidence?

Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 784 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free